Selected research
Market Structure
Global Arbidol Tablets (COVID-19) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Arbidol Tablets (COVID-19) market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Arbidol Tablets (COVID-19) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Arbidol Tablets (COVID-19) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Arbidol Tablets (COVID-19) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Arbidol Tablets (COVID-19) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Arbidol Tablets (COVID-19) include Simcere Pharmaceutical, CSPC Ouyi Pharmaceutical, Jiangsu Wuzhong Pharmaceutical and JSC Pharmstandard, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Arbidol Tablets (COVID-19) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Arbidol Tablets (COVID-19) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Arbidol Tablets (COVID-19) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Arbidol Tablets (COVID-19) market size, projected growth trends, production technologies, key applications, and end-use industries.
Arbidol Tablets (COVID-19) Segment by Company
Simcere Pharmaceutical
CSPC Ouyi Pharmaceutical
Jiangsu Wuzhong Pharmaceutical
JSC Pharmstandard
Arbidol Tablets (COVID-19) Segment by Type
50mg
100mg
Arbidol Tablets (COVID-19) Segment by Application
Anti Influenza Virus
COVID-19
Arbidol Tablets (COVID-19) Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Arbidol Tablets (COVID-19) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Arbidol Tablets (COVID-19) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Arbidol Tablets (COVID-19).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Arbidol Tablets (COVID-19) market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Arbidol Tablets (COVID-19) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Arbidol Tablets (COVID-19) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Arbidol Tablets (COVID-19) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- 50mg
- 100mg
Applications
- Anti Influenza Virus
- COVID-19
Companies covered
- Simcere Pharmaceutical
- CSPC Ouyi Pharmaceutical
- Jiangsu Wuzhong Pharmaceutical
- JSC Pharmstandard
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Arbidol Tablets (COVID-19) Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Arbidol Tablets (COVID-19) Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Arbidol Tablets (COVID-19) Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Arbidol Tablets (COVID-19) Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Arbidol Tablets (COVID-19) Market Dynamics
- 2.1 Arbidol Tablets (COVID-19) Industry Trends
- 2.2 Arbidol Tablets (COVID-19) Industry Drivers
- 2.3 Arbidol Tablets (COVID-19) Industry Opportunities and Challenges
- 2.4 Arbidol Tablets (COVID-19) Industry Restraints
3 Arbidol Tablets (COVID-19) Market by Manufacturers
- 3.1 Global Arbidol Tablets (COVID-19) Revenue by Manufacturers (2021-2026)
- 3.2 Global Arbidol Tablets (COVID-19) Sales by Manufacturers (2021-2026)
- 3.3 Global Arbidol Tablets (COVID-19) Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Arbidol Tablets (COVID-19) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Arbidol Tablets (COVID-19) Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Arbidol Tablets (COVID-19) Manufacturers, Product Type & Application
- 3.7 Global Arbidol Tablets (COVID-19) Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Arbidol Tablets (COVID-19) Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Arbidol Tablets (COVID-19) Players Market Share by Revenue in 2025
- 3.8.3 2025 Arbidol Tablets (COVID-19) Tier 1, Tier 2, and Tier 3
4 Arbidol Tablets (COVID-19) Market by Type
- 4.1 Arbidol Tablets (COVID-19) Type Introduction
- 4.1.1 50mg
- 4.1.2 100mg
- 4.2 Global Arbidol Tablets (COVID-19) Sales by Type
- 4.2.1 Global Arbidol Tablets (COVID-19) Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Arbidol Tablets (COVID-19) Sales by Type (2021-2032)
- 4.2.3 Global Arbidol Tablets (COVID-19) Sales Market Share by Type (2021-2032)
- 4.3 Global Arbidol Tablets (COVID-19) Revenue by Type
- 4.3.1 Global Arbidol Tablets (COVID-19) Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Arbidol Tablets (COVID-19) Revenue by Type (2021-2032)
- 4.3.3 Global Arbidol Tablets (COVID-19) Revenue Market Share by Type (2021-2032)
5 Arbidol Tablets (COVID-19) Market by Application
- 5.1 Arbidol Tablets (COVID-19) Application Introduction
- 5.1.1 Anti Influenza Virus
- 5.1.2 COVID-19
- 5.2 Global Arbidol Tablets (COVID-19) Sales by Application
- 5.2.1 Global Arbidol Tablets (COVID-19) Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Arbidol Tablets (COVID-19) Sales by Application (2021-2032)
- 5.2.3 Global Arbidol Tablets (COVID-19) Sales Market Share by Application (2021-2032)
- 5.3 Global Arbidol Tablets (COVID-19) Revenue by Application
- 5.3.1 Global Arbidol Tablets (COVID-19) Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Arbidol Tablets (COVID-19) Revenue by Application (2021-2032)
- 5.3.3 Global Arbidol Tablets (COVID-19) Revenue Market Share by Application (2021-2032)
6 Global Arbidol Tablets (COVID-19) Sales by Region
- 6.1 Global Arbidol Tablets (COVID-19) Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Arbidol Tablets (COVID-19) Sales by Region (2021-2032)
- 6.2.1 Global Arbidol Tablets (COVID-19) Sales by Region (2021-2026)
- 6.2.2 Global Arbidol Tablets (COVID-19) Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Arbidol Tablets (COVID-19) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Arbidol Tablets (COVID-19) Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Arbidol Tablets (COVID-19) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Arbidol Tablets (COVID-19) Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Arbidol Tablets (COVID-19) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Arbidol Tablets (COVID-19) Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Arbidol Tablets (COVID-19) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Arbidol Tablets (COVID-19) Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Arbidol Tablets (COVID-19) Revenue by Region
- 7.1 Global Arbidol Tablets (COVID-19) Revenue by Region
- 7.1.1 Global Arbidol Tablets (COVID-19) Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Arbidol Tablets (COVID-19) Revenue by Region (2021-2026)
- 7.1.3 Global Arbidol Tablets (COVID-19) Revenue by Region (2027-2032)
- 7.1.4 Global Arbidol Tablets (COVID-19) Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Arbidol Tablets (COVID-19) Revenue (2021-2032)
- 7.2.2 North America Arbidol Tablets (COVID-19) Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Arbidol Tablets (COVID-19) Revenue (2021-2032)
- 7.3.2 Europe Arbidol Tablets (COVID-19) Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Arbidol Tablets (COVID-19) Revenue (2021-2032)
- 7.4.2 Asia-Pacific Arbidol Tablets (COVID-19) Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Arbidol Tablets (COVID-19) Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Arbidol Tablets (COVID-19) Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Simcere Pharmaceutical
- 8.1.1 Simcere Pharmaceutical Company Information
- 8.1.2 Simcere Pharmaceutical Business Overview
- 8.1.3 Simcere Pharmaceutical Arbidol Tablets (COVID-19) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Simcere Pharmaceutical Arbidol Tablets (COVID-19) Product Portfolio
- 8.1.5 Simcere Pharmaceutical Recent Developments
- 8.2 CSPC Ouyi Pharmaceutical
- 8.2.1 CSPC Ouyi Pharmaceutical Company Information
- 8.2.2 CSPC Ouyi Pharmaceutical Business Overview
- 8.2.3 CSPC Ouyi Pharmaceutical Arbidol Tablets (COVID-19) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 CSPC Ouyi Pharmaceutical Arbidol Tablets (COVID-19) Product Portfolio
- 8.2.5 CSPC Ouyi Pharmaceutical Recent Developments
- 8.3 Jiangsu Wuzhong Pharmaceutical
- 8.3.1 Jiangsu Wuzhong Pharmaceutical Company Information
- 8.3.2 Jiangsu Wuzhong Pharmaceutical Business Overview
- 8.3.3 Jiangsu Wuzhong Pharmaceutical Arbidol Tablets (COVID-19) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Jiangsu Wuzhong Pharmaceutical Arbidol Tablets (COVID-19) Product Portfolio
- 8.3.5 Jiangsu Wuzhong Pharmaceutical Recent Developments
- 8.4 JSC Pharmstandard
- 8.4.1 JSC Pharmstandard Company Information
- 8.4.2 JSC Pharmstandard Business Overview
- 8.4.3 JSC Pharmstandard Arbidol Tablets (COVID-19) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 JSC Pharmstandard Arbidol Tablets (COVID-19) Product Portfolio
- 8.4.5 JSC Pharmstandard Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Arbidol Tablets (COVID-19) Value Chain Analysis
- 9.1.1 Arbidol Tablets (COVID-19) Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Arbidol Tablets (COVID-19) Production Mode & Process
- 9.2 Arbidol Tablets (COVID-19) Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Arbidol Tablets (COVID-19) Distributors
- 9.2.3 Arbidol Tablets (COVID-19) Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst